C12N 2710/16522
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16522 (New viral proteins or individual genes, new structural or functional aspects of) appears on 27 US grants and 31 published applications in this corpus.
Search patents in C12N- Granted patents
- 27
- Published applications
- 31
- Assignees
- 22
- Inventors
- 44
- Latest grant
- 29 Mar 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 1 |
| 2005 | 1 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 3 |
| 2010 | 0 | 2 |
| 2011 | 3 | 1 |
| 2012 | 0 | 3 |
| 2013 | 1 | 3 |
| 2014 | 0 | 3 |
| 2015 | 2 | 0 |
| 2016 | 1 | 1 |
| 2017 | 0 | 2 |
| 2018 | 1 | 0 |
| 2019 | 2 | 2 |
| 2020 | 3 | 3 |
| 2021 | 0 | 2 |
| 2022 | 1 | 1 |
| 2023 | 0 | 0 |
| 2024 | 0 | 2 |
By publication year. Applications have been published since 2001.
Recent patents
- Mesothelin vaccines and model systems29 Mar 2022US 11,285,197 B2The Johns Hopkins University
- Inhibition of TCR signaling with peptide variants21 Jan 2020US 10,538,558 B2Signablok, Inc.
- Method for diagnosing, treating, or preventing mood disorders21 Jan 2020US 10,539,578 B2Japan Tobacco Inc.
- Factor involved in latent infection with herpesvirus, and use thereof7 Jan 2020US 10,526,374 B2Japan Tobacco Inc.
- Factor involved in latent infection with herpes virus, and use thereof26 Nov 2019US 10,487,118 B2Japan Tobacco Inc.
- Peptides with anti-angiogenic activity21 Nov 2024US 2024/0382555 A1CHEIRONTECH S.r.l.
- Polypeptide11 Apr 2024US 2024/0117048 A1UCL Business PLC
- Inhibition Of TCR Signaling With Peptide Variants18 Aug 2022US 2022/0259267 A9Signablok, Inc.
- Modified t cells and methods of their use21 Oct 2021US 2021/0322473 A1The General Hospital Corporation
- Use of the u94 molecule of human herpesvirus 6 and derivatives thereof to increase or induce the expression of the hla-g molecule12 Aug 2021US 2021/0246456 A1
Most cited
By later US patents
- Screening method for chronic immune dysfunction syndrome35US 5,426,028 ARush-Presbyterian-St. Luke's Medical Center · 1995
- Screening kit and method for diagnosing chronic immune dysfunction syndrome34US 5,538,856 AThe Regents of the University of California · 1996
- Methods of detecting the presence of human herpesvirus-7 infection26US 5,230,997 AThe United States of America as represented by the Department of Health and Human Services · 1993
- Mesothelin vaccines and model systems6US 9,296,784 B2The Johns Hopkins University · 2016
- Antibodies against human herpesvirus-6(HHV-6) and method of use4US 6,054,283 AThe United States of America, as represented by the Secretary, Department of Health and Human Services · 2000